Soxgliflozin in the treatment of patients with diabetes and decompensated heart failure
- Why are vegetarians more likely to suffer from depression than meat eaters?
- Small wireless device implanted between skin and skull helps kill cancer cells
- Will the mRNA vaccine that can cure cancer come out near soon?
- Allogeneic T-cell therapy set for landmark first approval
- Boston University denies that the new COVID strain they made has 80% fatality rate
- A new generation of virus-free CAR-T cell therapy
Soxgliflozin in the treatment of patients with diabetes and decompensated heart failure
- First human trial of HIV gene therapy: A one-time cure will be achieved if successful!
- New breakthrough in CAR-T cell therapy: Lupus erythematosus patients achieved treatment-free remission for up to 17 months
- How long can the patient live after heart stent surgery?
- First time: Systemic multi-organ recovery after death
- Where do the bacteria in the human gut come from?
Soxgliflozin in the treatment of patients with diabetes and decompensated heart failure.
Recently, the “New England Journal” (NEJM) published online a SOLOIST-WHF trial study published by the Deepak Bhatt research team of the Cardiovascular Center of Harvard Brigham and Women’s Hospital.
2 Inhibitors can effectively reduce the incidence of combined events of cardiac death, hospitalization and emergency visits due to heart failure in the treatment of patients with diabetes and decompensated heart failure.
Image source: NEJM
Previous studies have shown that sodium-glucose cotransporter-2 inhibitors such as Soxaggliflozin can reduce the hospitalization rate and cardiogenic mortality of patients with stable heart failure.
However, the safety and effectiveness of the drug in the treatment of patients with diabetes and decompensated heart failure are still unknown.
The trial is a three-phase, double-blind, randomized, placebo-controlled trial.
The primary endpoint of the trial was originally designed to be the total number of first cardiovascular deaths or hospitalizations due to heart failure, which was later changed to cardiac deaths, hospitalizations due to heart failure and emergency department visits.
A total of 1,222 patients were included in the study, of which 608 were assigned to the Soxgliflozin group and 614 were assigned to the placebo group. During a median 9-month period, 245 patients in the Soxgliflozin group and 355 patients in the placebo group had a major outcome event.
The number of events in the Soxgliflozin group was lower than that in the placebo group (51.0 VS 76.3; hazard ratio, 0.67; 95% confidence interval, 0.52 to 0.85; P<0.001).
There was no statistical difference between the two groups in the number of cardiogenic deaths and the proportion of all-cause deaths per 100 patient-years.
Soxgliflozin in the treatment of patients with diabetes and decompensated heart failure
(source:internet, reference only)
Disclaimer of medicaltrend.org
